Five subtypes of melanocortin receptors (MC1-MC5 receptors) belonging to the superfamily of G-protein-coupled receptors (GPCRs) have been cloned and characterized. When stimulated by agonist ligands, the melanocortin receptors (MCRs) activate the cyclic adenosine monophosphate (cAMP) signal transduction pathway. The naturally occurring agonists of MCRs are melanocyte-stimulating hormones (a-MSH; Fig. 1 , b-MSH and g-MSH) and adrenocorticotropic hormone (ACTH), which are derived from proopiomelanocortin (POMC) by enzymatic processing. In addition, two endogenous antagonistic peptides, agouti and agouti-related protein (AGRP), have also been identified. The MCRs mediate a variety of physiological responses that include skin pigmentation (MC1 receptor), steroidogenesis (MC2 receptor), feeding behavior (MC3 and MC4 receptors), and exocrine gland secretion (MC5 receptor). Consequently, the melanocortin system has become an attractive therapeutic target for drug development. [1] [2] [3] [4] Over the last 30 years, significant progress has been made in the design of peptidic ligands as potential therapeutic agents for the treatment of melanocortin-mediated diseases. Among the first significant research findings on a-MSH was the discovery of [Nle 4 , D-Phe 7 ]a-MSH (NDP-MSH; Fig. 1 ).
Inverting Phe at position 7 of a-MSH to the D-isomer, in addition to replacing Met at position 4 with Nle, resulted in the formation of the analogue, NDP-MSH, that exhibited an enhanced potency for the MCRs and enzymatic stability. 5) Further studies on melanocortins indicate that the tetrapeptide His-Phe-Arg-Trp sequence is the minimal core sequence essential for the activation of the MCRs.
1) The tetrapeptide HisPhe-Arg-Trp sequence has thus been employed as a promising template for structure-activity relationship (SAR) studies of MCR ligands. [6] [7] [8] [9] Moreover, cyclic peptide analogues with reduced conformational freedom were designed to increase the activity and in vivo stability of the peptide ligands. Thus, both MT-II and SHU-9119 ( Fig. 1 ), which were designed based on the cyclization of the tetrapeptide His-DPhe-Arg-Trp sequence, were discovered as cyclic peptides with potent activities on the MCRs. 10, 11) Among the MCRs, numerous studies have suggested that the MC4 receptor is involved in the regulation of feeding behavior and energy homeostasis. [12] [13] [14] [15] [16] [17] [18] It has also been reportedly involved in the regulation of sexual functions 19, 20) and protection against tumor-induced decreases in body weight. 21, 22) In addition, the MC4 receptor has been a focus of interest for its possible relationship to stress and the regulation of emotional behavior in relation to conditions such as depression and anxiety. [23] [24] [25] [26] [27] [28] [29] These findings till date indicate that the MC4 receptor could be a promising target for the development of drugs for the above-mentioned conditions, and numerous ligands of the MC4 receptor have been reported. Stress is considered to play a pivotal role in both anxiety and depression. Indeed, dysfunction of the hypothalamic-pituitary-adrenal (HPA) axis, which is caused by continuous exposure to stress, has been reported in patients with major depressive disorders. Stress responses are initiated by the release of corticotropin-releasing factor (CRF). In addition of CRF system activation, several lines of evidence suggest that melanocortins mediate important behavioral and biochemical responses to stress and, consequently, stress-induced disorders.
We previously reported that a tripeptide MC4 receptor antagonist 3e (MCL0020) exhibited antidepressant, anxiolytic, and anti-stress effects in a variety of animal models (Table  1) . 26) These findings suggest that blockade of the MC4 receptor may be a useful approach for treating subjects with depressive and anxiety disorders. This hypothesis is supported by the demonstration in various rodent modes of depression and anxiety that other MC4 receptor antagonists also exert antidepressant and anxiolytic effects. 27, 28) In the present study, to identify small molecular MC4 receptor ligands, we focused our attention on a tripeptide sequence, D-Phe-Arg-Trp, and modified both the D-Phe and Trp residues to increase the affinity for the MC4 receptor. Moreover, to reduce the peptidic character and molecular weight, the effects of the removing the N-or C-terminus of the tripeptides on the binding affinity for the receptor were explored. The synthesis, SARs and biological evaluation of the arginine analogues as MC4 receptor ligands are described in this study.
Chemistry All the compounds were prepared from BocArg(Z) 2 -OH 4 according to the general synthetic methods (Methods A and B) described as Charts 1 and 2. The reaction of 4 with H-2-Nal-NH 2 · HCl 11a in the presence of HOBt and EDC yielded Boc-Arg(Z) 2 -2-Nal-NH 2 5a. After the removal of the Boc group of 5a by TFA, condensation with Boc-D-2-Nal-OH 12 in the presence of HOBt and EDC yielded Boc-D-2-Nal-Arg(Z) 2 -2-Nal-NH 2 6a-1. The removal of the Boc group of 6a-1 by TFA, followed by the treatment with Ac 2 O and pyridine, yielded Ac-D-2-Nal-Arg(Z) 2 -2-Nal-NH 2 7a-1. Compound 3e was obtained by the removal of the Z groups of 7a-1 using hydrogenolysis with Pd(OH) 2 as a catalyst. Compounds 3a-d and 3f-h were also obtained from 4 by using similar synthetic methods to those of 3e (Method A, Chart 1).
Compounds 9 and 10 were synthesized from 5a using a synthetic method similar to Method A. The removal of the Boc group of 5a under acidic conditions, followed by condensation with 2-naphthyl-(CH 2 ) 2 -CO 2 H 15 in the presence of HOBt and EDC, yielded 2-naphthyl-(CH 2 ) 2 -Arg(Z) 2 -2-Nal-NH 2 8-1. Compound 9 was obtained by the removal of the Z groups of 8-1 using hydrogenolysis. Compound 10 was also obtained from 5a by the same synthetic method as that used for 9. Furthermore, compound 20 was prepared from Boc-Arg(Z) 2 -NH-(CH 2 ) 2 -2-naphthyl 5c using a synthetic method similar to that used for 9 (Method B, Chart 2).
Results and Discussion
The affinities of all the compounds for the MC4 receptor were evaluated based on their binding affinity to the membranes of COS-1 cells expressing the human MC4 receptor; the affinities were calculated from the inhibition curve of [ 125 I]NDP-a-MSH binding, 27) and the IC 50 values are shown in Table 1 .
All endogenous agonists for the MCRs contain a tetrapeptide sequence, His-Phe-Arg-Trp, which has been identified as the minimal peptide sequence crucial for MCRs activation. Further studies have shown that the inversion of the chirality of Phe to D-Phe results in an increase in the binding affinity for the MC4 receptor, as described above. Moreover, the His residue in tetrapeptide 1 (Fig. 1) , which showed a moderate affinity (IC 50 ϭ1153 nM) for the MC4 receptor, can be deleted without much loss in binding affinity (tripeptide 2; IC 50 ϭ2081 nM, Fig. 1 ). 8) Therefore, in the present study, to explore potent and small molecular MC4 receptor ligands, we focused our attention on mimicking the tripeptide, D-PheArg-Trp sequence.
It has been suggested that the chemically reactive indol in the Trp residue could be replaced with a non-reactive naphthyl moiety in the design of peptide melanocortin receptor ligands. 6) In our attempt to identify further potent tripeptide analogues, we initially anticipated that 2-Nal could be used as an alternative to the Trp in the tripeptide, Ac-D-Phe-ArgTrp-NH 2 2. We prepared the tripeptides 3a (containing 2-Nal) and 3b (containing D-2-Nal), as shown in Chart 1, and evaluated their affinity for the MC4 receptor. The resultant 3a and 3b were found to exhibit a similar affinity (IC 50 ϭ 1070 and 2170 nM, respectively) for the MC4 receptor, compared to the corresponding tripeptide 2. These findings suggest that Trp can be replaced with 2-Nal or D-2-Nal without any significant decrease in binding affinity for the MC4 receptor in these tripeptide analogues. Therefore, both 2-Nal and D-2-Nal were employed in further research efforts to design tripeptides for MC4 receptor ligands.
We next considered that the D-Phe in these tripeptides could be replaced with D-Nal, based on previous SAR observations of cyclic peptides, MT-II and SHU-9119 (Fig. 1) . 10, 11) We prepared 3c-f as shown in Chart 1 and evaluated the affinity for the MC4 receptor. The results indicated that both 3e and 3f containing D-2-Nal showed a much higher affinity (IC 50 ϭ15.4 and 36.5 nM, respectively) for the MC4 receptor than the D-Phe analogues, 3a and 3b. In contrast, both 3c and 3d containing D-1-Nal exhibited a slightly higher affinity (IC 50 ϭ327 and 690 nM, respectively) for the MC4 receptor than the corresponding 3a and 3b. These findings suggest that, in the case of these tripeptide analogues, the substitution of D-2-Nal at position 7 (a-MSH numbering; Fig. 1 ) resulted in a drastic increase in the binding affinity for the MC4 receptor.
To better understand the minimal structure fragment required for binding affinity for the MC4 receptor, we initially investigated the effect of removing the N-terminus from 3c and 3e on the binding affinity for the receptor. We prepared dipeptides 9 and 10, as shown in Chart 2, and evaluated the binding affinity for the MC4 receptor. The results indicated that the resultant 9 and 10 showed a much lower affinity (IC 50 ϭ543 and 3940 nM, respectively) for the MC4 receptor than the corresponding tripeptides 3c and 3e. Next, we also investigated the effect of removing the C-terminus from 3a and 3e on binding affinity for the MC4 receptor. The results indicated that the dipeptide 3g showed a relatively high affinity (IC 50 ϭ117 nM) for the MC4 receptor. This finding suggests that dipeptide analogues, as exemplified by 3g, might serve as new templates for the design of potent MC4 ligands with reduced peptidic character.
As an additional structural conversion to further reduce the peptidic character and molecular weight, we prepared 20, which was simplified by removing the N-terminus from the relatively high-affinity dipeptide 3g, and evaluated the affinity for the MC4 receptor. Surprisingly, compound 20 exhibited a moderate affinity for the MC4 receptor (IC 50 ϭ 1610 nM), and the affinity was almost the same as that of tetrapeptide 1 and tripeptide 2. Thus, analogues like 20, which have a significantly reduced peptidic character, might also be useful as new frameworks for MC4 ligands.
We previously reported that 3e was selective for the MC4 receptor and acted as an antagonist at the MC4 receptor. 3e was also found to exhibit antidepressant and anxiolytic activities in various rodent models. 26) To further investigate the in vitro profiles of the compounds described above, the effects of several compounds on cAMP formation at a ligand concentration of 10 mM in MC4 receptor expressing COS-1 cells were evaluated ( Table 1 ). The results indicated that the tripeptides 3c and 3d containing D-1-Nal at position 7 (a-MSH numbering) increased cAMP formation, suggesting a) The fold increase vs. basal level at a ligand concentration of 10 mM.
that these compounds act as agonists at the MC4 receptor. In contrast, the tripeptides 3e and 3f containing D-2-Nal at position 7 did not influence the stimulation of cAMP, suggesting that these compounds act as antagonists at the MC4 receptor. These findings suggest that, in the case of these tripeptide analogues, the substituted position (1Ј vs. 2Ј) of the naphthyl ring of Nal residue at position 7 appears to be important for the determining of agonist and antagonist activity at the MC4 receptor; these results were supported by SAR research on the cyclic peptides, MT-II and SHU-9119.
10,11)

Conclusion
We have reported on the synthesis and SARs of a new series of tripeptides that act as MC4 receptor ligands. The lead compound 3a, obtained by replacing a Trp residue of tripeptide 2 with 2-Nal, showed a moderate affinity for the MC4 receptor. Structural conversion led to the identification of a compound with a high affinity for the MC4 receptor, namely, 3e (IC 50 ϭ15.4 nM), which showed a 70-fold higher affinity for the MC4 receptor than the lead compound 3a. We also found a dipeptide analogue, 3g, with a reduced peptidic character that showed a relatively high affinity (IC 50 ϭ117 nM) for the MC4 receptor. Furthermore, in the case of these tripeptide analogues, the substituted position (1Ј vs. 2Ј) of the naphthyl ring of Nal residue at position 7 was found to be important for the differentiation of agonist and antagonist activity at the MC4 receptor. These arginine analogues that have been shown to have a high affinity for the MC4 receptor may be excellent tools for investigating the involvement of the MC4 receptor in the development of stress-related disorders, such as depression and anxiety, and for elucidating the actions mediated by the MC4 receptor.
Experimental
Melting points were determined on a Yanaco MP-500D melting point apparatus and are uncorrected. Proton nuclear magnetic resonance ( 1 H-NMR) spectra were obtained using a Varian Gemini 2000 (200 MHz) or Varian Unity Inova 300 (300 MHz). Chemical shifts are reported in parts per million relative to tetramethylsilane (TMS) as an internal standard. Mass spectra (MS) were obtained on Micromass Platform LC (ESI). High resolution spectra were recorded on a Micromass Q-TOF2 instrument. Elemental analyses were performed by a Perkin-Elmer 2400 or a Yanaco MT-6. Silica gel C-200 (100-200 mesh, Wako Pure Chemical) and Chromatorex NH (100-200 mesh, Fuji Silysia Chemical Ltd.) were used for column chromatography, using the solvent systems (volume ratios) indicated below.
General Method for the Synthesis of 3a-3h (Method A). H-2-Nal-NH 2 Hydrochloride (11a) A mixture of Boc-2-Nal-OH (5.00 g, 15.9 mmol), methyl iodide (5.00 ml, 80.3 mmol) and NaHCO 3 (2.66 g, 31.7 mmol) in DMF (25 ml) was stirred at room temperature for 72 h. The reaction mixture was concentrated in vacuo and partitioned between EtOAc and H 2 O. The separated organic phase was washed with 5% aq. KHSO 4 , saturated aq. NaHCO 3 and brine, dried over Na 2 SO 4 , filtered, and concentrated in vacuo. A solution of the above residue in MeOH (50 ml) was saturated by NH 3 with ice-cooling. The reaction mixture was standed at room temperature for 24 h, and concentrated in vacuo. To the residue was added a solution of 4 mol/l HCl in 1,4-dioxane (80 ml), and the reaction mixture was stirred at room temperature for 2 h. After concentration of the reaction mixture, the residual solid was dissolved in MeOH (50 ml) followed by filtration, and the filtrate was concentrated in vacuo. To the residual solid was added IPA (20 ml) and refluxed for 10 min. The resulting suspension was stirred at room temperature for 15 h, and the precipitate was collected by filtration to obtain 11a (3.77 g, 95%) as a solid. 1 Boc-D-2-Nal-Arg(Z) 2 -2-Nal-NH 2 (6a-1) To a suspension of BocArg(Z) 2 -2-Nal-NH 2 5a (500 mg, 0.676 mmol) in CH 2 Cl 2 (5 ml) was added TFA (5 ml) and the reaction mixture was stirred at room temperature for 2 h. After concentration of the reaction mixture, the residue was partitioned between CHCl 3 and saturated aq. NaHCO 3 . The separated organic phase was dried over Na 2 SO 4 , filtered, concentrated in vacuo to obtain crude HArg(Z) 2 -2-Nal-NH 2 . To a mixture of the crude H-Arg(Z) 2 -2-Nal-NH 2 , Boc-D-2-Nal-OH 12 (235 mg, 0.745 mmol) and HOBt · H 2 O (156 mg, 1.02 mmol) in DMF (15 ml) was added EDC · HCl (162 mg, 0.846 mmol) with ice-cooling, and the reaction mixture was stirred at room temperature for 15 h. The mixture was partitioned between EtOAc and H 2 O. The separated organic phase was washed with 5% aq. KHSO 4 , saturated aq. NaHCO 3 and brine, dried over Na 2 SO 4 , filtered, concentrated in vacuo. The residue was chromatographed on Silica gel C-200 (CHCl 3 /MeOH 50 : 1), and crystallized from EtOAc to give 6a-1 (227 mg, 38%) as a solid. Ac-D-2-Nal-Arg(Z) 2 -2-Nal-NH 2 (7a-1) To a suspension of Boc-D-2-Nal-Arg(Z) 2 -2-Nal-NH 2 6a-1 (200 mg, 0.214 mmol) in CH 2 Cl 2 (3 ml) was added TFA (3 ml) and the reaction mixture was stirred at room temperature for 1 h. After concentration of the reaction mixture, the residue was partitioned between CHCl 3 and saturated aq. NaHCO 3 . The separated organic phase was dried over Na 2 SO 4 , filtered, concentrated in vacuo to obtain crude H-D-2-Nal-Arg(Z) 2 -2-Nal-NH 2 . To a solution of the crude H-D-2-NalArg(Z) 2 -2-Nal-NH 2 in CHCl 3 (2 ml) was added a mixture of Ac 2 O (24 mg, 0.235 mmol) and pyridine (19 mg, 0.235 mmol) in CHCl 3 (1 ml), and the reaction mixture was stirred at room temperature for 2 h. After concentration of the reaction mixture, the residue was partitioned between EtOAc and 5% aq. KHSO 4 . The separated organic phase was washed with saturated aq. NaHCO 3 and brine, dried over Na 2 SO 4 , filtered, concentrated in vacuo. The residue was crystallized from EtOAc to obtain 7a-1 (139 mg, 74%) as a solid. Ac-D-2-Nal-Arg-2-Nal-NH 2 Hydrochloride (3e) A suspension of Ac-D-2-Nal-Arg(Z) 2 -2-Nal-NH 2 7a-1 (120 mg, 0.137 mmol) and Pd(OH) 2 /C (20 wt% Pd on carbon, wet) (100 mg) in a mixture of MeOH (20 ml) and THF (10 ml) was stirred under hydrogen atmosphere for 15 h. The mixture was filtered through Celite and the filtrate was concentrated in vacuo. To the residue was added 4 M HCl in 1,4-dioxane (0.10 ml), and the mixture was concentrated in vacuo. To the residual solid was added IPE, and the resulting suspension was stirred at room temperature for 1 h, and the precipitate was collected by filtration to obtain 3e (85 mg, 95%) as a solid. Arg(Z) 2 -2-Nal-NH 2 (6a-3 22 (2H, m), 1.42-1.60 (1H, m), 1.98 (3H, s), 2.88-2.99 (2H, m), 3.08-3.39 (3H, m), 3.58-3.66 (1H, m), 3.69-3.90 (1H, m), 4.21-4.31 (1H, m) Ac-D-Phe-Arg-2-Nal-NH 2 Hydrochloride (3a) Compound 3a was obtained as a solid from Ac-D-Phe-Arg(Z) 2 -2-Nal-NH 2 7a-3 by similar synthetic method of 3e. Ac-D-1-Nal-Arg-2-Nal-NH 2 Hydrochloride (3c) Compound 3c was obtained as a solid from Ac-D-1-Nal-Arg(Z) 2 -2-Nal-NH 2 7a-2 by similar synthetic method of 3e. Ac-D-2-Nal-Arg-D-2-Nal-NH 2 Hydrochloride (3f) Compound 3f was obtained as a solid from Ac-D-2-Nal-Arg(Z) 2 -D-2-Nal-NH 2 7b-1 by similar synthetic method of 3e. Ac-D-1-Nal-Arg(Z) 2 -D-2-Nal-NH 2 (7b-2) Compound 7b-2 was obtained as a solid from Boc-D-1-Nal-Arg(Z) 2 -D-2-Nal-NH 2 6b-2 by similar synthetic method of 7a-1. BSA, after which the filters were washed three times with the buffer. Radioactivity was quantified in a g-counter. Nonspecific binding was determined in the presence of 1 mM [Nle 4 ,D-Phe 7 ]a-MSH. Specific binding was determined by subtracting nonspecific from total binding. In the competition assay, concentration of the test compound that caused 50% inhibition of the specific binding (IC 50 value) was determined from each concentration-response curve.
Synthesis of 3a. Boc-D-Phe-
Determination of cAMP COS-1 cells transiently expressing the MC4 receptor and grown in a six-well plate were used. The culture medium was removed, the cells were washed with phosphate buffered saline, and 1 ml of DMEM containing 1 mM isobutylmethylxanthine, a phosphodiesterase inhibitor, was added. The cells were incubated with 10 mM concentration of the test compound for 15 min at 37°C. The culture medium was then aspirated and the cells were washed with phosphate buffered saline. Two milliliters of ice-cold 65% ethanol were added, and the cells were scraped from the wells. The supernatant was collected by centrifugation at 15000 rpm for 15 min at 4°C. cAMP formed in the cells was determined using a commercially available cAMP EIA system.
